Wang, Charlie http://orcid.org/0000-0001-8728-4330
Zoungas, Sophia
Yan, Mabel
Wolfe, Rory
Haydon, Andrew
Shackleton, Mark
Voskoboynik, Mark
Moore, Maggie
Andrews, Miles C.
Nicholls, Stephen J.
Mar, Victoria
Article History
Received: 25 May 2022
Accepted: 15 November 2022
First Online: 2 December 2022
Declarations
:
: Approval for this study was obtained from The Alfred Hospital Human Ethics Committee (Project 183/21). This study was conducted in accordance with the ethics standards of the institutional research committee and the Declaration of Helsinki. Patients in the VMS Clinical Database had provided written informed consent to participate including the use of clinical data for research purposes, and to be contacted for ongoing research follow-up.
: All participants in this study provided written informed consent for the publication of de-identified clinical data.
: CW – None.SZ – No personal conflicts of interest. Her institution (Monash University) receives funding from NHMRC, MRFF, Victorian Department of Health and Human Services, as well as Eli Lilly Australia Ltd., Boehringer-Ingelheim, MSD Australia, Astra Zeneca, Novonordisk, Sanofi and Servier for unrelated work.MY – None.RW – None.AH – None.MS – Received research support, speaking fees, honoraria or travel support from Novartis, Roche, BMS, Illumina, MSD, Merck, and Pierre Fabre.MV – Honoraria from MSD; Consultant/Advisory role for AstraZeneca.MM- None.MCA – Research support, advisory board, honoraria from MSD Australia unrelated to the current work.SN—Research support from AstraZeneca, Amgen, Anthera, CSL Behring, Cerenis, Eli Lilly, Esperion, Resverlogix, Novartis, InfraReDx and Sanofi-Regeneron and is a consultant for Amgen, Akcea, AstraZeneca, Boehringer Ingelheim, CSL Behring, Eli Lilly, Esperion, Kowa, Merck, Takeda, Pfizer, Sanofi-Regeneron and Novo Nordisk.KYVM − None.